<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on February 03, 2023</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00460382</url>
  </required_header>
  <id_info>
    <org_study_id>2007-000670-23</org_study_id>
    <secondary_id>ANRS 139 TRIO</secondary_id>
    <nct_id>NCT00460382</nct_id>
  </id_info>
  <brief_title>Clinical Trial to Assess the Efficacy of Darunavir/Ritonavir (DRV/r), Etravirine (ETV) and Raltegravir (MK-0518) in HIV Patients With Resistant Viruses</brief_title>
  <acronym>ANRS139 TRIO</acronym>
  <official_title>Prospective Clinical Trial to Assess Safety and Efficacy of DRV/r(TMC 114/r), ETV(TMC 125) and MK-0518 in Addition to OBT in HIV-1 Infected Patients With Limited to No Treatment Options ANRS 139 TRIO</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>French National Agency for Research on AIDS and Viral Hepatitis</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Merck Sharp &amp; Dohme LLC</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
    <collaborator>
      <agency>Janssen-Cilag Tibotec</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>French National Agency for Research on AIDS and Viral Hepatitis</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to look at the safety and efficacy of a combination of 3 new&#xD;
      antiretroviral drugs: darunavir, etravirine and MK-0518 (raltegravir) in patients who have&#xD;
      multi-resistant viruses and limited treatment options. An optimized background regimen that&#xD;
      may include nucleoside reverse transcriptase inhibitors (NRTIs) and enfuvirtide can be added,&#xD;
      if possible, to this combination. Patients will undergo treatment for 48 weeks and&#xD;
      virological efficacy will be evaluated at week 24.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Methods: A phase II pilot, prospective, open label, single arm multicentric clinical trial&#xD;
      assessing a darunavir/ritonavir, etravirine and MK-0518-containing regimen, if possible&#xD;
      associated to an optimized background regimen that may include NRTIs and enfuvirtide, in&#xD;
      HIV-1 infected patients failing combination antiretroviral therapy with multi-resistant&#xD;
      viruses.&#xD;
&#xD;
      Treatment strategy: Patients will receive raltegravir (MK-0518), darunavir/ritonavir&#xD;
      (TMC114/r) and etravirine (TMC125) and if possible an optimized background therapy.&#xD;
&#xD;
        -  raltegravir (MK-0518) (400 mg x 2/d = one 400 mg pill twice daily)&#xD;
&#xD;
        -  darunavir (600 mg x 2/d= two 300 mg pills twice daily with meal)&#xD;
&#xD;
        -  ritonavir (100 mg x 2/d = one 100 mg pill twice daily with meal)&#xD;
&#xD;
        -  etravirine (200 mg x 2/d = two 100 mg pills twice daily with meal)&#xD;
&#xD;
        -  if possible an optimized background therapy: may include NRTI(s) and enfuvirtide but not&#xD;
           nonnucleoside reverse transcriptase inhibitors (NNRTIs) and protease inhibitors (PIs).&#xD;
           NRTIs choice is left to the clinician's discretion. Enfuvirtide is highly recommended in&#xD;
           enfuvirtide-naive patients but is left to the clinician.&#xD;
&#xD;
      Main outcome: proportion of patients with HIV RNA levels of less than 50 copies/ml in an&#xD;
      intent to treat analysis at W24.&#xD;
&#xD;
      Secondary outcomes: proportions of patients with HIV RNA levels of less than 50 copies/ml at&#xD;
      week 48, with HIV RNA levels of less than 400 copies/ml at week 24 and 48; HIV RNA level&#xD;
      evolution between baseline and week 48; HIV proviral DNA and 2LTR circle HIV DNA between&#xD;
      baseline and week 48; number and type of resistance mutations in case of virologic failure&#xD;
      occurrence; CD4 lymphocyte count and proportion evolution between baseline and week 48; HIV&#xD;
      infection progression; frequency of the study regimen modifications and interruption; study&#xD;
      regimen tolerance; study regimen adherence; association between study drugs' minimum&#xD;
      concentrations at week 4 and virologic success at week 24; evolution of pharmacokinetic&#xD;
      parameters of study drugs between week 1 and week 4 in the Pharmacokinetic substudy.&#xD;
&#xD;
      Sample size: 103 patients&#xD;
&#xD;
      Enrollment period: 24 weeks&#xD;
&#xD;
      Patient's participation duration: 52 weeks&#xD;
&#xD;
      An extended follow-up (from week 52 to week 96) has been added in April 2008.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>May 2007</start_date>
  <completion_date type="Actual">September 2009</completion_date>
  <primary_completion_date type="Actual">March 2008</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Proportion of patients with HIV RNA levels of less than 50 copies/ml in an intent to treat analysis at week 24</measure>
    <time_frame>week 24</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Proportions of patients with HIV RNA levels of less than 50 copies/ml at week 48, with HIV RNA levels of less than 400 copies/ml at weeks 24 and 48</measure>
    <time_frame>week 24 and 48</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>HIV RNA level evolution between baseline and week 48</measure>
    <time_frame>from week 0 to 48</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>HIV proviral DNA and 2LTR circle HIV DNA between baseline and week 48</measure>
    <time_frame>from week 0 to 48</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number and type of resistance mutations in case of virologic failure occurrence</measure>
    <time_frame>from week 0 to 48</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>CD4 lymphocyte count and proportion evolution between baseline and week 48</measure>
    <time_frame>from week 0 to 48</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>HIV infection progression</measure>
    <time_frame>from week 0 to 48</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Frequency of the study regimen modifications and interruption</measure>
    <time_frame>from week 0 to 48</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Study regimen tolerance</measure>
    <time_frame>from week 0 to 48</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Study regimen adherence</measure>
    <time_frame>from week 0 to 48</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Association between study drugs' minimum concentrations at week 4 and week 12 and virologic success at week 24</measure>
    <time_frame>from week 4 to 24</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Evolution of pharmacokinetics parameters of study drugs in the PK substudy</measure>
    <time_frame>betwwen week 1 and 4</time_frame>
  </secondary_outcome>
  <enrollment type="Actual">103</enrollment>
  <condition>HIV Infections</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>raltegravir potassium</intervention_name>
    <description>400 mg twice a day</description>
    <other_name>Isentress</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>darunavir/ritonavir</intervention_name>
    <description>2 pills of 300 mg twice a day</description>
    <other_name>Prezista</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>etravirine</intervention_name>
    <description>2 pills of 100 mg twice a day</description>
    <other_name>TMC125</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Optimized background regimen</intervention_name>
    <description>NRTIs and or enfuvirtide (investigator choice)</description>
    <other_name>OBT</other_name>
    <other_name>enfuvirtide</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Age: 18 years and above&#xD;
&#xD;
          -  Documented HIV-1 infection.&#xD;
&#xD;
          -  History of virological failure on NNRTIs (patients with a history of toxicity to&#xD;
             nevirapine and efavirenz may be enrolled in this study).&#xD;
&#xD;
          -  On a combination antiretroviral therapy for at least 8 weeks prior to the screening&#xD;
             visit (if on tipranavir, or enfuvirtide these drugs should have been introduced more&#xD;
             than 8 weeks before the screening visit).&#xD;
&#xD;
          -  Patient naive to darunavir, etravirine and to integrase inhibitors&#xD;
&#xD;
          -  Plasma viral load at screening visit over 1000 copies/ml, (no CD4 restriction).&#xD;
&#xD;
          -  Genotypic resistance testing at the screening visit:&#xD;
&#xD;
               -  Protease inhibitor mutations: over or equal to 3 primary protease inhibitor&#xD;
                  mutations among: D30N, V32I, L33F, M46I/L, I47A/V, G48V, I50L/V, I54M, L76V,&#xD;
                  V82A/F/L/T/S, I84V, N88S and L90M (IAS list 2006) but below or equal to 3&#xD;
                  mutations among the following: V11I, V32I, L33F, I47V, I50V, I54L/M, G73S, L76V,&#xD;
                  I84V et L89V (virus sensitivity to darunavir/ritonavir).&#xD;
&#xD;
               -  Reverse transcriptase mutations: over or equal to 3 NRTI mutations (among IAS&#xD;
                  list) and below or equal to 3 mutations among: A98G, L100I, K101Q/P/E,&#xD;
                  K103H/N/S/T, V106A/M, V108I, E138G/K/Q, V179D/E/F/G/I, Y181C/I/V/C/H/L,&#xD;
                  Y188C/H/L, G190A/C/E/Q/S, P225H, F227C/L, M230I/L, P236L, K238N/T and Y318F&#xD;
                  (virus sensitivity to etravirine)&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Non effective barrier contraception in women of child bearing potential&#xD;
&#xD;
          -  Pregnant women or women who are breastfeeding&#xD;
&#xD;
          -  Opportunistic infection at the acute phase&#xD;
&#xD;
          -  Decompensated cirrhosis (stage B or C of Child-Pugh score)&#xD;
&#xD;
          -  Malignancy requiring chemotherapy or radiotherapy&#xD;
&#xD;
          -  Contraindicated medications being taken by the patient (listed in protocol)&#xD;
&#xD;
          -  Allergy to the active substances and expedients of darunavir, etravirine and&#xD;
             raltegravir.&#xD;
&#xD;
          -  Haemoglobin &lt; 7g/dl, neutrophil cell count &lt; 500/mm3, platelets &lt; 50,000/mm3,&#xD;
             creatinine clearance &lt; 50 ml/mn, P. alkaline, AST, ALT or total bilirubin over or&#xD;
             equal to 3 times normal values.&#xD;
&#xD;
          -  Patients receiving experimental agents with an exclusion period for participation in&#xD;
             other studies applicable at the screening visit of the current study.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Yazdan YAZDANPANAH, MD PHD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Hôpital Tourcoing FRANCE</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Geneviève CHENE, MD PHD</last_name>
    <role>Study Director</role>
    <affiliation>INSERM U897 BORDEAUX FRANCE</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Hôpital Gustave Dron, Service Maladies Infectieuses</name>
      <address>
        <city>Tourcoing</city>
        <zip>59208</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>September 2010</verification_date>
  <study_first_submitted>April 12, 2007</study_first_submitted>
  <study_first_submitted_qc>April 12, 2007</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 13, 2007</study_first_posted>
  <last_update_submitted>September 16, 2010</last_update_submitted>
  <last_update_submitted_qc>September 16, 2010</last_update_submitted_qc>
  <last_update_posted type="Estimate">September 17, 2010</last_update_posted>
  <responsible_party>
    <name_title>French National Agency for Research on AIDS and Viral Hepatitis</name_title>
    <organization>French National Agency for Research on AIDS and Viral Hepatitis</organization>
  </responsible_party>
  <keyword>HIV infections</keyword>
  <keyword>HIV integrase inhibitor</keyword>
  <keyword>etravirine</keyword>
  <keyword>darunavir</keyword>
  <keyword>MK 0518</keyword>
  <keyword>raltegravir</keyword>
  <keyword>Treatment Experienced</keyword>
  <keyword>Antiviral drug resistance</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>HIV Infections</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ritonavir</mesh_term>
    <mesh_term>Darunavir</mesh_term>
    <mesh_term>Raltegravir Potassium</mesh_term>
    <mesh_term>Enfuvirtide</mesh_term>
    <mesh_term>Etravirine</mesh_term>
  </intervention_browse>
  <pending_results>
    <submitted>August 11, 2011</submitted>
    <returned>September 14, 2011</returned>
    <submitted>December 21, 2011</submitted>
    <returned>January 20, 2012</returned>
    <submitted>July 16, 2012</submitted>
    <returned>August 17, 2012</returned>
    <submitted>November 6, 2012</submitted>
    <returned>December 3, 2012</returned>
    <submitted>July 17, 2013</submitted>
    <submission_canceled>Unknown</submission_canceled>
    <submitted>January 7, 2014</submitted>
    <returned>February 21, 2014</returned>
  </pending_results>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

